Forteo Dosage/Direction for Use

The recommended dose of FORTEO is 20 micrograms administered once daily by subcutaneous injection in the thigh or abdomen.
Patients must be trained to use the proper injection techniques (see Cautions For Usage). A User Manual is also available to instruct patients on the correct use of the pen.
Data support continuous treatment with FORTEO for 18 up to 24 months (see Precautions).
Patients should receive supplemental calcium and vitamin D supplements if dietary intake is inadequate.
Following cessation of FORTEO therapy, patients can be treated with other osteoporosis therapies to maintain or further increase bone mineral density (see Pharmacology: Pharmacodynamics under Actions).
Use in renal impairment: FORTEO should not be used in patients with severe renal impairment (see Contraindications). In patients with moderate renal impairment, Forteo should be used with caution.
Use in hepatic impairment: No data are available in patients with impaired hepatic function (see Pharmacology: Toxicology: Pre-Clinical Safety Data under Actions).
Specific populations: Children: There is no experience in children. FORTEO should not be used in paediatric patients or young adults with open epiphyses.
Elderly patients: Dosage adjustment based on age is not required (See Pharmacology: Pharmacokinetics under Actions).